Since the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed
numerous and exciting developments in chronic thromboembolic pulmonary hypertension (…

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease with poor
prognosis if not treated. The treatment of choice is surgery with pulmonary endarterectomy…

Background Treatments for pulmonary arterial hypertension have been mainly studied in
patients with advanced disease (WHO functional class [FC] III and IV). This study was designed …

… Riociguat was also associated with significant improvements in the NT-proBNP level (P<0.001)
and WHO functional class (P=0.003). The most common serious adverse events were …

Background Current therapies for pulmonary arterial hypertension have been adopted on the
basis of short-term trials with exercise capacity as the primary end point. We assessed the …

… Dr Jansa has received grants for serving as investigator in an investigator-initiated trial (Treprostinil
in CTEPH) and speaker and investigator fees from Bayer . Dr Ambroz received …

Background— Chronic thromboembolic pulmonary hypertension, a rare complication of acute
pulmonary embolism, is characterized by fibrothrombotic obstructions of large pulmonary …

… Jansa has received honoraria from Actelion Pharmaceuticals and fees for consultancies
from Actelion, Pfizer, GlaxoSmithKline, and AOP Orphan Pharmaceuticals. Dr. Torbicki has …

Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of inoperable
and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). In the …